Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

BackgroundSevere asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of debate. Indeed, switching between biologics is com...

Full description

Bibliographic Details
Main Authors: Cristiano Caruso, Paolo Cameli, Elena Altieri, Maria Aliani, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Giorgio Walter Canonica, Stefano Centanni, Maria D’Amato, Stefano Del Giacco, Fausto De Michele, Elide Anna Pastorello, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Marco Caminati, Alessandra Vultaggio, Alessandro Zullo, Sara Rizzoli, Silvia Boarino, Gianfranco Vitiello, Francesco Menzella, Fabiano Di Marco
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Medicine
Subjects:
severe eosinophilic asthma
switch
benralizumab
observational
biologics
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.950883/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.950883/full

Similar Items